Covaxin shows 77.8% efficacy in phase 3 trial data in review by expert committee

Covaxin, India’s only homemade COVID-19 vaccine, has shown 77.8 per cent efficacy in phase 3 trial data in review by the DCGI’s Subject Expert Committee, source said this afternoon. Hyderabad-based Bharat Biotech, the manufacturer of the made-in-India COVID-19 vaccine, recently submitted phase 3 trial data to DCGI, the country’s apex drug regulator. Covaxin, the indigenously-developed COVID-19 vaccine, is among the three vaccines currently being used in … Continue reading Covaxin shows 77.8% efficacy in phase 3 trial data in review by expert committee